Dr. Shah on LV20.19 CAR T-cell Therapy in R/R MCL

Video

Nirav N. Shah, MD, discusses findings from a phase 1/2 study of lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens in patients with relapsed or refractory mantle cell lymphoma.

Nirav N. Shah, MD, associate professor, Medical College of Wisconsin, discusses findings from a phase 1/2 study (NCT04186520) of lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens (LV20.19 CAR) in patients with relapsed or refractory mantle cell lymphoma (MCL).

This single-center, prospective study was designed as a 14-patient, single-stage, phase 2 trial, with a target 3-month complete response (CR) rate of 50% based on the CR rate seen with ibrutinib (Imbruvica) in patients with relapsed/refractory MCL in the phase 2 PCYC-1104-CA trial (NCT01236391), Shah says. In PCYC-1104-CA, the overall response rate (ORR) was 68% with a CR rate of 21% in patients who received ibrutinib. This phase 1/2 study of LV20.19 CAR was designed to be positive if 6 or more patients achieved a CR by 90 days, Shah explains.

Patients enrolled to this trial had a median age of 63 years and a median of 5 prior lines of therapy. All patients had received a prior BTK inhibitor, and 11 patients had progressed on this therapy. Five patients had also progressed on the non-covalent BTK inhibitor pirtobrutinib (Jaypirca), which they received in a previous clinical trial.

The trial met its primary end point. At day 28, the ORR was 100%, with 71% of patients achieving a CR and 29% of patients achieving a partial response (PR), Shah emphasizes. In addition, of the 12 patients assessed for minimal residual disease (MRD), 9 were MRD negative between days 28 and 65 post-CAR T-cell therapy. At day 90, the ORR remained at 100%, with some patients converting from a PR to a CR, bringing the CR rate up to 92%, Shah says. In the phase 2 cohort, 8 patients have achieved a 90-day CR so far, Shah notes.

Additionally, at a median follow-up of 22 months, of the 14 patients treated with LV20.19 CAR, 1 patient had relapsed, Shah concludes.

Related Videos
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH